weiss.nyu1 weiss.nyu1
ok kill everything else but wait for FDA to allow a therapeutic dose and f'in see if it works
thought greenwood had mentioned that he thought he was going to get the green light from fda to test in other types of spinal cord injuries and even maybe MS..Hopefully someone piks up where Geron left off..
once all these idiot panic sellers sell their shares off Big Pharma will step in and do the stem cell trials
greenwood seemed excited about getting to therapeutic dose..this company has switched being about the science to being..about $$$ ..dont like it .. Chip better have this thing go over 5 bucks soon..
"How could they not wait for a therapeutic dose of OPC1"************************************************Maybe they had inside information that the FDA was never going to allow therapeutic dosing or was going to delay it indefinitely. Look we are over 3 years out since the trial was initially approved and the FDA had to be dragged kicking and screaming to allow even the safety trial. There is huge resistance to ESC research and it ain't the religious right, it is big pharma.Do you know how much money big pharma would lose if spinal cord injuries were cured???
While the FDA played a role, the program was stopped because of a whole host of issues. Remember, it took a long time to get that drug into patients because they initially had issues with contamination. In essence, they had to break down their whole manufacturing process and improve the product. This pushed them back over a year. Considering the huge potential benefits to patients, I think its likely the FDA would fast track this drug, once the safety data were evaluated. For now, its just a matter of cost. However, if they'd kept it on board for another two years and shown efficacy -- even anecdotal, leaked information, then we wouldn't be having this discussion.
Why wasn't one site enough? Arrogance of prior exec,IMHO
More LinksSummaryHistorical PricesInteractive ChartHeadlinesMarket PulseCompetitorsKey StatisticsInsider TransactionsIncome StatementBalance SheetCashflowTechnical Analysis Top Stories Siegel: In ‘first inning’ of shift that's great for stocks CEO pay climbs again, even as their stock prices don't Jeweler Tiffany posts steepest sales drop since financial crisis Fed just amassing ammo for next recession with summer hike: Forester The biggest college apparel deal ever isn't such a big deal Gov't report: Feds spend billions to run ancient technology 2.92May 24 4:00 PMEDT
weiss.nyu1 weiss.nyu1
ok kill everything else but wait for FDA to allow a therapeutic dose and f'in see if it works
thought greenwood had mentioned that he thought he was going to get the green light from fda to test in other types of spinal cord injuries and even maybe MS..Hopefully someone piks up where Geron left off..
once all these idiot panic sellers sell their shares off Big Pharma will step in and do the stem cell trials
greenwood seemed excited about getting to therapeutic dose..this company has switched being about the science to being..about $$$ ..dont like it .. Chip better have this thing go over 5 bucks soon..
"How could they not wait for a therapeutic dose of OPC1"************************************************Maybe they had inside information that the FDA was never going to allow therapeutic dosing or was going to delay it indefinitely. Look we are over 3 years out since the trial was initially approved and the FDA had to be dragged kicking and screaming to allow even the safety trial. There is huge resistance to ESC research and it ain't the religious right, it is big pharma.Do you know how much money big pharma would lose if spinal cord injuries were cured???
While the FDA played a role, the program was stopped 
because of a whole host of issues. Remember, it took a long time to get that drug into patients because they initially had issues with contamination. In essence, they had to break down their whole manufacturing process and improve the product. This pushed them back over a year. Considering the huge potential benefits to patients, I think its likely the FDA would fast track this drug, once the safety data were evaluated. For now, its just a matter of cost. However, if they'd kept it on board for another two years and shown efficacy -- even anecdotal, leaked information, then we wouldn't be having this discussion.
Why wasn't one site enough? Arrogance of prior exec,IMHO
More LinksSummaryHistorical PricesInteractive ChartHeadlinesMarket PulseCompetitorsKey StatisticsInsider TransactionsIncome StatementBalance SheetCashflowTechnical Analysis Top Stories Siegel: In ‘first inning’ of shift that's great for stocks CEO pay climbs again, even as their stock prices don't Jeweler Tiffany posts steepest sales drop since financial crisis Fed just amassing ammo for next recession with summer hike: Forester The biggest college apparel deal ever isn't such a big deal Gov't report: Feds spend billions to run ancient technology 2.92May 24 4:00 PMEDT